Literature DB >> 23578383

Oxidative stress induced by inactivation of TP53INP1 cooperates with KrasG12D to initiate and promote pancreatic carcinogenesis in the murine pancreas.

Talal Al Saati1, Pascal Clerc, Naïma Hanoun, Sylvain Peuget, Hubert Lulka, Véronique Gigoux, Florence Capilla, Benoît Béluchon, Anne Couvelard, Janick Selves, Louis Buscail, Alice Carrier, Nelson Dusetti, Marlène Dufresne.   

Abstract

Tumor protein p53-induced nuclear protein 1 (TP53INP1) is involved in cell stress response. Its expression is lost at the pancreatic intraepithelial neoplasia 1b (PanIN1b)/PanIN2 stage of pancreatic carcinogenesis. Our objective was to determine whether TP53INP1 loss of expression contributes to pancreatic cancer formation in a conditional KrasG12D mouse model. We generated Kras-INP1KO mice using LSL-Kras(G12D/+);Pdx1-Cre(+/-) mice (Kras mice) and TP53INP1(-/-) mice. Analysis of pancreases during ageing shows that in the presence of activated Kras, TP53INP1 loss of expression accelerated PanIN formation and increased pancreatic injury and the number of high-grade lesions as compared with what occurs in Kras mice. Moreover, cystic lesions resembling intraductal papillary mucinous neoplasm (IPMN) were observed as early as 2 months of age. Remarkably, TP53INP1 is down-regulated in human IPMN. Activation of the small GTPase Rac1 shows that more oxidative stress is generated in Kras-INP1KO than in Kras mice pancreas despite elevated levels of the Nrf2 antioxidant regulator. We firmly establish the link between Kras-INP1KO pancreatic phenotype and oxidative stress with rescue of the phenotype by the antioxidant action of N-acetylcysteine. Our data provide in vivo functional demonstration that TP53INP1 deficiency accelerates progression of pancreatic cancer, underlining its role in the occurrence of IPMN and highlighting the importance of TP53INP1 in the control of oxidative status during development of pancreatic cancer.
Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23578383     DOI: 10.1016/j.ajpath.2013.02.034

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  17 in total

1.  First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings.

Authors:  Louis Buscail; Barbara Bournet; Fabienne Vernejoul; Gilles Cambois; Hubert Lulka; Naïma Hanoun; Marlène Dufresne; Aline Meulle; Alix Vignolle-Vidoni; Laetitia Ligat; Nathalie Saint-Laurent; Frédéric Pont; Sébastien Dejean; Marion Gayral; Frédéric Martins; Jérôme Torrisani; Odile Barbey; Fabian Gross; Rosine Guimbaud; Philippe Otal; Frédéric Lopez; Gérard Tiraby; Pierre Cordelier
Journal:  Mol Ther       Date:  2015-01-14       Impact factor: 11.454

Review 2.  Deconstructing networks of p53-mediated tumor suppression in vivo.

Authors:  Alyssa M Kaiser; Laura D Attardi
Journal:  Cell Death Differ       Date:  2017-11-03       Impact factor: 15.828

Review 3.  Targeting reactive oxygen species in development and progression of pancreatic cancer.

Authors:  Nisha Durand; Peter Storz
Journal:  Expert Rev Anticancer Ther       Date:  2016-11-23       Impact factor: 4.512

4.  Pigment Epithelium-derived Factor (PEDF) Blocks Wnt3a Protein-induced Autophagy in Pancreatic Intraepithelial Neoplasms.

Authors:  Jingjing Gong; Glenn Belinsky; Usman Sagheer; Xuchen Zhang; Paul J Grippo; Chuhan Chung
Journal:  J Biol Chem       Date:  2016-08-24       Impact factor: 5.157

Review 5.  Synthetic Vulnerabilities in the KRAS Pathway.

Authors:  Marta Roman; Elizabeth Hwang; E Alejandro Sweet-Cordero
Journal:  Cancers (Basel)       Date:  2022-06-08       Impact factor: 6.575

6.  Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program.

Authors:  Kathryn T Bieging-Rolett; Alyssa M Kaiser; David W Morgens; Anthony M Boutelle; Jose A Seoane; Eric L Van Nostrand; Changyu Zhu; Shauna L Houlihan; Stephano S Mello; Brian A Yee; Jacob McClendon; Sarah E Pierce; Ian P Winters; Mengxiong Wang; Andrew J Connolly; Scott W Lowe; Christina Curtis; Gene W Yeo; Monte M Winslow; Michael C Bassik; Laura D Attardi
Journal:  Mol Cell       Date:  2020-11-05       Impact factor: 17.970

7.  KRas, ROS and the initiation of pancreatic cancer.

Authors:  Peter Storz
Journal:  Small GTPases       Date:  2016-05-24

Review 8.  p53 and Tumor Suppression: It Takes a Network.

Authors:  Anthony M Boutelle; Laura D Attardi
Journal:  Trends Cell Biol       Date:  2021-01-28       Impact factor: 20.808

9.  Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions.

Authors:  Geou-Yarh Liou; Heike Döppler; Kathleen E DelGiorno; Lizhi Zhang; Michael Leitges; Howard C Crawford; Michael P Murphy; Peter Storz
Journal:  Cell Rep       Date:  2016-03-03       Impact factor: 9.423

Review 10.  Cytoprotection "gone astray": Nrf2 and its role in cancer.

Authors:  Claudia Geismann; Alexander Arlt; Susanne Sebens; Heiner Schäfer
Journal:  Onco Targets Ther       Date:  2014-08-26       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.